Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.475
Buy
RSI(14)
56.446
Neutral
STOCH(KDJ)(9,3,3)
67.421
Sell
ATR(14)
2.646
Low Volatility
CCI(14)
70.205
Neutral
Williams %R
38.877
Buy
TRIX(12,20)
0.340
Sell
StochRSI(14)
0.000
Sell
Phibro Animal Health Corp
PAHC53.880USD
-1.940-3.48%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
2.09BMarket Cap
23.71P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Phibro Animal Health Corp
Currency: USD Updated: 2026-03-27Key Insights
Phibro Animal Health Corp's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 18 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 45.33.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Phibro Animal Health Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Phibro Animal Health Corp Highlights
StrengthsRisks
Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. It develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. It markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. It has three segments: Animal Health, Mineral Nutrition and Performance Products. Its Animal Health segment develops, manufactures and markets about 280 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. The Mineral Nutrition segment is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 32.55% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.30B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 40.30%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 40.30%.
Fairly Valued
The company’s latest PE is 23.71, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 20.14M shares, decreasing 15.15% quarter-over-quarter.
Held by Paul Tudor Jones
Star Investor Paul Tudor Jones holds 10.22K shares of this stock.
Analyst Rating
Based on
4
analysts
Hold
Current Rating
45.333
Target Price
-18.29%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of Phibro Animal Health Corp is 8.17, ranking 68 out of 157 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 373.91M, representing a year-over-year increase of 20.90%, while its net profit experienced a year-over-year increase of 762.14%.
Score
Financials
4.99
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.81
Operational Efficiency
10.00
Growth Potential
9.69
Shareholder Returns
8.38
Phibro Animal Health Corp's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of Phibro Animal Health Corp is 7.86, ranking 44 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 23.71, which is 1484.41% below the recent high of 375.69 and 55.73% above the recent low of 10.50.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 18/157
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of Phibro Animal Health Corp is 6.00, ranking 133 out of 157 in the Pharmaceuticals industry. The average price target is 45.00, with a high of 50.00 and a low of 32.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
4
analysts
Hold
Current Rating
45.333
Target Price
-18.29%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Phibro Animal Health Corp
PAHC
4
Biogen Inc
BIIB
37
Amgen Inc
AMGN
36
Eli Lilly and Co
LLY
35
Vertex Pharmaceuticals Inc
VRTX
33
Gilead Sciences Inc
GILD
32
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of Phibro Animal Health Corp is 9.37, ranking 3 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 59.26 and the support level at 46.87, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
55.198
Sell
MA10
53.504
Buy
MA20
51.950
Buy
MA50
48.819
Buy
MA100
44.843
Buy
MA200
39.141
Buy
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of Phibro Animal Health Corp is 10.00, ranking 1 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 97.68%, representing a quarter-over-quarter decrease of 8.50%. The largest institutional shareholder is The Vanguard, holding a total of 1.53M shares, representing 7.44% of shares outstanding, with 0.06% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Acadian Asset Management LLC
Geode Capital Management, L.L.C.
Dimensional Fund Advisors, L.P.
Fidelity Management & Research Company LLC
Nuveen LLC
1
2
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Phibro Animal Health Corp is 6.53, ranking 53 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.69. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Phibro Animal Health Corp’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
Score
Beta vs S&P 500 index
0.69
VaR
+4.01%
240-Day Maximum Drawdown
+18.72%
240-Day Volatility
+50.02%
Return
Best Daily Return
60 days
+21.95%
120 days
+21.95%
5 years
+31.81%
Worst Daily Return
60 days
-6.25%
120 days
-7.82%
5 years
-18.52%
Sharpe Ratio
60 days
+2.79
120 days
+1.57
5 years
+0.54
Risk Assessment
Maximum Drawdown
240 days
+18.72%
3 years
+37.28%
5 years
+68.04%
Return-to-Drawdown Ratio
240 days
+11.10
3 years
+2.53
5 years
+0.24
Skewness
240 days
+2.26
3 years
+2.11
5 years
+1.78
Volatility
Realised Volatility
240 days
+50.02%
5 years
+46.25%
Standardised True Range
240 days
+2.88%
5 years
+1.60%
Downside Risk-Adjusted Return
120 days
+313.05%
240 days
+313.05%
Maximum Daily Upside Volatility
60 days
+53.25%
Maximum Daily Downside Volatility
60 days
+34.71%
Liquidity
Average Turnover Rate
60 days
+0.74%
120 days
+0.67%
5 years
--
Turnover Deviation
20 days
+59.71%
60 days
+47.60%
120 days
+34.82%
Peer Comparison
Pharmaceuticals
Phibro Animal Health Corp
PAHC
7.95 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Innoviva Inc
INVA
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
8.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
